Eli Lilly and Company (LLY)
Eli Lilly and Company Revenue Growth: -4.06%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
LLY Revenue Growth Rankings
| Overall | 23rd percentile | 3335 of 4358 |
| Sector | 23rd percentile | 349 of 456 in Healthcare |
| Industry | 16th percentile | 15 of 18 in Drug Manufacturers - Major |
LLY Revenue Growth Range, Past 5 Years
| Minimum | -4.06% | Mar 2012 |
| Maximum | 22.24% | Dec 2007 |
| Average | 8.45% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these LLY related companies
LLY News
Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
May 24, 9:02AM Street Insider
May 24, 9:02AM Street Insider
Pharma has been a place to hide in pullback, but there are many fewer names that look healthy. $PFE still holding, $LLY looks ready to drop
about 7 days ago by harmongreg
about 7 days ago by harmongreg
$PFE $LLY $GSK So this is the condition some drug commercials warned us about! And we thought they were kidding. http://stks.co/3q2n
about 11 days ago by laughing_stock
about 11 days ago by laughing_stock
The Drama Continues At $AMLN: Takeover Still Likely. $BMY $LLY $SNY http://stks.co/3prL
about 11 days ago by abubnic
about 11 days ago by abubnic
Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
May 14, 9:00AM PR Newswire
May 14, 9:00AM PR Newswire
Ex-Dividend Stocks: DuPont, AK Steel http://stks.co/3lBo My story via @TheStreet $DD $AKS $LLY $BTU $EXC $HLF #ExDividend #Dividend
about 16 days ago by azendrian
about 16 days ago by azendrian
$LLY MACDBullish Trend Chart pat UpTrend RSI Bullish Up/Down vol pat under Accum 50/200d MA Bullish Support 39.47 above Resis 40.12 Bullis
about 20 days ago by MACDaddy
about 20 days ago by MACDaddy
5 Dividend Stocks With Excellent Gross Margins
$ADI $BLK $CA $LLY $WM http://stks.co/3grM
about 20 days ago by Dividendinvestor
about 20 days ago by Dividendinvestor
Stock Trading Ideas for the Week of 5/7/12 http://stks.co/3gjx via @alphatrends $LLY $ARBA $MM
about 20 days ago by StockTwits
about 20 days ago by StockTwits
Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
May 03, 11:21AM PR Newswire
May 03, 11:21AM PR Newswire
FDA Approves Amyvid for Alzheimer’s Diagnosis. $LLY http://stks.co/3ZNn
about 27 days ago by abubnic
about 27 days ago by abubnic
News related to $LLY, currently +0.3% since open: 'ImmunoGen fiscal 3Q loss widens as expenses rise' http://stks.co/3YQK
about 29 days ago by TradeBot
about 29 days ago by TradeBot
$LLY another strong healthcare name trying to breakout. Low volatility also vs SPX. $XLV http://stks.co/3Xg3
about 30 days ago by tradewithpete
about 30 days ago by tradewithpete
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| LLY | 41.11 | -0.05 | -0.12% | 47.70B |
| LLNW | 2.71 | -0.02 | -0.73% | 282.44M |
| LIVE | 6.13 | +0.16 | +2.68% | 14.41M |
| LINTA | 17.24 | +0.13 | +0.76% | 9.411B |
| LIFE | 41.83 | -0.18 | -0.43% | 7.457B |
| LG | 38.16 | -0.13 | -0.34% | 858.22M |
| LEDR | 4.46 | -0.05 | -1.11% | 113.51M |
| LEA | 41.01 | +0.51 | +1.26% | 4.119B |
| LCUT | 11.21 | -0.07 | -0.62% | 139.34M |
| LCI | 4.10 | +0.10 | +2.50% | 116.28M |
